AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00574496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Study NCT00574496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Study NCT00574496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Study NCT00574496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT00574496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Study NCT00574496 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Study NCT01793519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Subcutaneous
Study NCT01793519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Infusion
Study NCT01793519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Subcutaneous
Study NCT02092077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: somatropin
Description: Dose may be adjusted as required
Study NCT00166283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: memory retraining exercises
Description: Memory retraining exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
Study NCT00166283 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo control memory exercises
Description: Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
Study NCT01198275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: n-3 PUFAs
Description: 1.0 g of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) in the average ratio EPA/DHA of 0.19:1.5, one capsule twice a day
Study NCT01198275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1.0 g of olive oil,one capsule twice a day
Study NCT01198275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RASS inhibitors and/or RAS blockers
Description: Patients on ACE-Is or ARBs were continued on the same agent. In those who were not on therapy, an ACE-I or an ARB was started. In all patients, an effort was made to achieve the highest tolerated dose.
Study NCT01198275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RASS inhibitors and/or RAS blockers
Description: Patients on ACE-Is or ARBs were continued on the same agent. In those who were not on therapy, an ACE-I or an ARB was started. In all patients, an effort was made to achieve the highest tolerated dose.
Study NCT01198275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Patients on amiodarone were continued at a maintenance dose of 200 mg daily, whereas those who were not taking amiodarone were started at a dose of 400 mg daily for 1 week and then continued on a maintenance dose of 200 mg daily.
Study NCT01198275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amiodarone
Description: Patients on amiodarone were continued at a maintenance dose of 200 mg daily, whereas those who were not taking amiodarone were started at a dose of 400 mg daily for 1 week and then continued on a maintenance dose of 200 mg daily.
Study NCT00837746 — intervention group
Intervention type: DRUG
Intervention: risedronate
Description: risedronate tablet, 5 mg daily or 35 mg once weekly for 5 years
Study NCT00150176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine - Open Label
Description: Open Label Phase: All subjects received 26 weeks of open label asenapine treatment (cross titration period up to first 4 weeks, with target dose of 10 mg twice daily by week 1).
Study NCT00150176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Asenapine - Open Label
Description: Open Label Phase: All subjects received 26 weeks of open label asenapine treatment (cross titration period up to first 4 weeks, with target dose of 10 mg twice daily by week 1).
Study NCT00150176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Double Blind
Description: Double Blind Phase: Following Open Label Phase, matching placebo sublingual twice daily for 26 weeks.
Study NCT00150176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine - Double Blind
Description: Double Blind Phase: Following the Open Label Phase, asenapine 5 or 10 mg sublingual twice daily for 26 weeks.
Study NCT02797717 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy:
Description: All patients will have 2 OPEAcycles(chemotherapy cycle:Vincristine,Etoposide,Prednisone,doxorubicin) ,After assignment ( by randomization) to one of the arms the patient will be treated accordingly . response assessment will be done after OPEA cycles (ERA) and after cycles of copdac 28 or DECOPDAC 21(LRA).according to the assessments results patients will have radiotherapy or not.
Study NCT03415984 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fundus autofluorescence imaging
Description: Fundus autofluorescence imaging
Study NCT04075552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre Meal Presentation
Description: Pre-Meal Presentation. In the Pre-Meal Presentation (PMP) condition, school staff delivered the plate of vegetable pieces prior to students regularly scheduled lunchtime (about 5 min). Like baseline, no programmed consequences were provided for student interaction or consumption of the vegetables.
Study NCT04075552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre Meal Presentation + Modeling
Description: Similar to the prior condition, each participant will be offered a plate containing target foods for 4 min. Once the plate has been delivered to each participant, a staff person will model eating the food. The model will have an identical plate of food. Within six feet of students oriented towards the model (i.e., the students will be facing the model), the model will pick up one piece of food, say Yum, this looks good in a loud and excited tone, eat it, and then deliver a soft prompt to the participants to try it (e.g., You should try this!). Staff will avoid giving a firm/hard demand (e.g., Eat the food). Repeat this for four pieces of food, alternating between the two target foods, with about 10-20 sec between each bite. Repeat the model as necessary based on the room arrangement, such that each students contacts the model within six feet while oriented towards the model.
Study NCT04075552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre Meal Presentation + Token Economy
Description: Similar to prior condition, expect each participant can earn tokens for eating food items. Tokens can be exchanged for small prizes (e.g., pencil or sticker) at the end of a session.
Study NCT02797717 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy:
Description: All patients will have 2 OPEAcycles(chemotherapy cycle:Vincristine,Etoposide,Prednisone,doxorubicin) ,After assignment ( by randomization) to one of the arms the patient will be treated accordingly . response assessment will be done after OPEA cycles (ERA) and after cycles of copdac 28 or DECOPDAC 21(LRA).according to the assessments results patients will have radiotherapy or not.
Study NCT02797717 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Description: ARM A and ARM B
Study NCT04062682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Diet
Description: Receive counseling to meet guidelines for healthy dietary patterns
Study NCT02194569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrate
Study NCT02797717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: ARM A and ARM B
Study NCT02797717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: ARM B , 100mg/m2/day
Study NCT02797717 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: ARM A and ARM B , 40mg/m2/day p.o
Study NCT02797717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: ARM A and ARM B , 40mg/m2/day p.o
Study NCT02797717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: ARM B , 25mg/m2
Study NCT02797717 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dacarbazine
Description: ARM A and ARM B , 250mg/m2 i.v
Study NCT02797717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: ARM A and ARM B , 250mg/m2 i.v
Study NCT02797717 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: ARM A and ARM B , 625mg/m2 i.v
Study NCT02797717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: ARM A and ARM B , 625mg/m2 i.v
Study NCT00212745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Andrews/Reiter behavioral treatment for epilepsy
Description: The behavioral intervention in this study uses lifestyle counseling to avoid triggers for seizures and strategies to stop beginning seizures. Participants are taught to practice meditative relaxation exercises.
Study NCT01109745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PELICAN Primary Care
Description: The intervention is the integration of the output of the Pelican instrument in daily care to guide disease management for children with asthma treated in primary care. The general practitioner can integrate the information of the Pelican instrument in their consultation and disease management decisions. The general practitioner will be trained and supported to negotiate the child's, and physicians' agendas based on the outcome of the instrument, and discuss possible interventions. All participating children of a GP will be allocated to the same treatment group (i.e., hierarchical or nested design).
Study NCT01109745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PELICAN Secondary Care
Description: The intervention is the integration of the output of the Pelican instrument in daily care to guide disease management for children with asthma treated in secondary care. The nurse can integrate the information of the Pelican instrument in their consultation and disease management decisions. The paediatricians will be trained and supported to negotiate the child's, and nurses' agendas based on the outcome of the instrument, and discuss possible interventions.
Study NCT03019614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Generic hydrocortisone
Study NCT03019614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronocort
Description: Modified formulation of hydrocortisone
Study NCT01793519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT01958866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinospora Crispa-extract Product
Study NCT00913133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desirudin
Description: Desirudin SC 15mg q12h
Study NCT02646267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard intensity warfarin
Description: target international normalised ratio(INR) was 2.1-3.0
Study NCT02646267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low intensity warfarin
Description: target international normalised ratio(INR) was 1.7-2.2
Study NCT02646267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dabigatran etexilate
Description: 110mg, twice a day, oral
Study NCT03943979 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cognitive Training
Description: Cognitive Training (CT): 4 consecutive days, 30-45 min session involving 5 different tasks designed to train executive functions and attention, available at the Guttmann Neuropersonaltrainer platform (computerized cognitive training tool certified by the Spanish Agency for Medicines and Health Products as a Class I Health Product). The difficulty level of all the tasks was automatically adjusted on a trial-by-trial basis for both Active and Active Control conditions.
Study NCT01958866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Study NCT01958866 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00446550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afegostat tartrate
Study NCT03943979 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Cognitive Training (CT): 4 consecutive days, 30-45 min session involving 5 different tasks designed to train executive functions and attention, available at the Guttmann Neuropersonaltrainer platform (computerized cognitive training tool certified by the Spanish Agency for Medicines and Health Products as a Class I Health Product). The difficulty level of all the tasks was automatically adjusted on a trial-by-trial basis for both Active and Active Control conditions.
Study NCT03943979 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial Direct-Current Stimulation (tDCS)
Description: tDCS: 4 consecutive days, 20 min session, delivered through multichannel tDCS (Starstim, Neuroelectrics), with an excitatory target over the r-dlPFC, and an inhibitory target on the contralateral lobe (l-dlPFC). The positioning of the multichannel tCS (electrode location and currents) was solved using the Stimweaver (Ruffini 2013). The resulting tCS montage employed 8 gelled Ag/AgCl electrodes of π cm2 size (Pistim, Neuroelectrics) placed at AF3(-1093uA), AF4 (1178uA), F3 (-1161uA), F4 (1104uA), F7 (-414uA), F8 (530uA), FC5 (1189uA), FC6 (-1332uA).
Study NCT00642746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. In addition to the active ingredient, erlotinib contains lactose (hydrous), microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, and magnesium stearate.~Tablets containing 25 mg, 100 mg, and 150 mg of erlotinib are available. Each bottle will contain 30 tablets, a quantity sufficient for 4 consecutive weeks of dosing, with overage.
Study NCT00642746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Antimetabolite used as a chemotherapy. Administered intravenously as a bolus injection at 400mg/m2 on Day 1 followed by 2400 mg/m2 continuously over 46 hours.
Study NCT00642746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Chemotherapy agent given as a supplement to Fluorouracil. Given intravenously 400mg/m2 in combination with Fluorouracil dosing.
Study NCT03248271 — intervention group
Intervention type: DRUG
Intervention: Insulin Lispro
Description: Insulin
Study NCT01574339 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoStim LES Stimulation System
Description: The EndoStim LES Stimulation System comprises three components: an electrical stimulation lead, an implantable pulse generator (IPG) and an external programmer.~The IPG and stimulation lead are to be implanted within the subject's body using conventional laparoscopy. The device programmer is to be used by the study investigator and/or a company technical representative.
Study NCT03646136 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retained fluid
Description: Retained fluid
Study NCT03646136 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Emptied fluid
Description: Emptied fluid
Study NCT04218110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic
Description: Application of antiseptic drug to the inguinal area of the subjects
Study NCT04218110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prevantics 3.15 % / 70 % Swabstick
Description: Application of antiseptic drug to the inguinal area of the subjects
Study NCT02598596 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegloticase
Description: Pegloticase, IV
Study NCT02598596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Azathioprine (1.25 mg/kg, followed by 2.5 mg/kg) oral, daily
Study NCT03881449 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ABILIFY MYCITE
Description: Initiation of ABILIFY MYCITE will commence immediately, with subjects wearing the patch and using the smartphone app for a total of 3 months from baseline visit to the 3 month visit. Following the initial 90-days, the physician and patient may determine to use ABILIFY MYCITE anytime during the following 9 months. Following this period (up to 12 months), the subjects will not use ABILIFY MYCITE and return to standard care. A safety follow-up phone call will occur at 2 weeks after the 12 month/early termination (ET) visit. In addition, individuals in the ABILIFY MYCITE arm will evaluate satisfaction with the use of ABILIFY MYCITE.
Study NCT03446859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS
Description: First, there was explanation of the overall test procedure. The subject was placed in supine lying in a comfortable position.A pair of electrodes (inactive electrodes) was placed a little below the umbilicus (Right and Left) and the other pair (active electrode) along the inguinal region at the level of pubic symphysis (Right and Left) according to (Akinbo et al 2000).~The TENS equipment was switched on and the intensity was set at a level tolerable by each participant's. The treatment period lasted for 30 minutes for each treatment sessions and the procedure was carried out once a day on the 1st, 3rd and 5th days (Akinbo et.al 2000). Pain intensity was measured pre treatment and post treatment each day of treatment using the visual analogue scale (VAS).
Study NCT04094532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Ultrasound guided 20 ml % 0.250 bupivacaine injection to transverse thoracic muscle plane bilaterally
Study NCT04094532 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Ultrasound guided 20 ml % 0.9 saline injection to transverse thoracic muscle plane bilaterally
Study NCT01066923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daily aspirin (ASA)
Description: Two weeks 82 mg aspirin taken orally prior to exercise protocol
Study NCT01066923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active cooling
Description: Active cooling to remediate heat stress following exercise by placing hands and forearms into cold water
Study NCT01066923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acute aspirin (ASA)
Description: 325 mg chewable aspirin administered immediately following exercise
Study NCT01066923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive cooling
Description: Removing protective garments for passive cooling following exercise
Study NCT01066923 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Passive cooling
Description: Removing protective garments for passive cooling following exercise
Study NCT01066923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daily placebo
Description: Placebo comparator for daily aspirin therapy
Study NCT01066923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Daily placebo
Description: Placebo comparator for daily aspirin therapy
Study NCT01066923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acute placebo
Description: Placebo comparator for acute aspirin therapy
Study NCT01066923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acute placebo
Description: Placebo comparator for acute aspirin therapy
Study NCT02769468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Back
Study NCT02769468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chest
Study NCT02769468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Left Axilla
Study NCT03270124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Activity Goal
Description: Patients are given a tailored daily activity goal in terms of steps per day for which to aim.
Study NCT03270124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercises
Description: Patients will instructed to perform 3 different resistance exercises targeting muscles pertinent to activities of daily living on 6 out of 7 days a week.
Study NCT03270124 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily Activity Recording
Description: A Fitbit will be worn by all participants to record daily activity.
Study NCT03270124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Activity Recording
Description: A Fitbit will be worn by all participants to record daily activity.
Study NCT04571606 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single injection peripheral nerve block with liposomal bupivacaine (Exparel)
Description: 10 mL/133 mg liposomal bupivacaine and 10 mL 0.5% bupivacaine
Study NCT04571606 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single injection peripheral nerve block with 0.25% bupivacaine and subsequent peripheral nerve catheter with 0.2% bupivacaine infusion via onQ pain pump
Description: 20 mL 0.25% bupivacaine block and subsequent 10 mL/hr 0.2% bupivacaine infusion for 48 hours
Study NCT03489915 — intervention group
Intervention type: DEVICE
Intervention: OCT
Description: Assessment of macular edema secondary to retinal vein occlusion usin optical coherence tomography and its correlation with visual acuity